TSLPR Human
Description
TSLPR is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Product Specs
Product Science Overview
Thymic stromal lymphopoietin (TSLP) is a cytokine that plays a crucial role in the immune system, particularly in the development and progression of allergic diseases and asthma. TSLP is primarily produced by epithelial cells and acts as a potent activator of the immune system. The receptor for TSLP, known as the thymic stromal lymphopoietin receptor (TSLPR), is a key component in the signaling pathway of this cytokine.
TSLP was first identified in the conditioned medium from a murine thymic stromal cell line as a growth factor for B and T cells. The human homolog of TSLP was later discovered using computational methods to screen human genomic databases for sequences similar to mouse TSLP . TSLP exerts its biological effects by binding to a high-affinity heteromeric receptor complex composed of the TSLP receptor chain and the interleukin-7 receptor alpha chain (IL-7Rα) .
TSLP is primarily expressed by epithelial cells, including those in the lungs, intestines, and skin. It can also be produced by dendritic cells, mast cells, and other immune cells . TSLP plays a critical role in initiating and maintaining type 2 immune responses, which are associated with allergic diseases and asthma. The binding of TSLP to its receptor complex activates downstream signaling pathways that lead to the production of pro-inflammatory cytokines and chemokines .
There are two main isoforms of TSLP: the long form (lfTSLP) and the short form (sfTSLP). The long form is upregulated in inflammatory conditions, while the short form is expressed under steady-state conditions and plays a homeostatic role . The expression of TSLP is regulated by various factors, including cytokines, microbial products, and environmental stimuli.
TSLP has been implicated in a variety of allergic diseases, such as atopic dermatitis, bronchial asthma, and eosinophilic esophagitis. It is also involved in chronic inflammatory disorders, autoimmune diseases, and certain cancers . The broad pathophysiologic profile of TSLP has made it a target for therapeutic interventions. Tezepelumab, a human monoclonal antibody that inhibits TSLP, has shown efficacy in treating severe uncontrolled asthma .
